Medicinal chemistry beyond KRAS: CDK2, WEE1, SERD
zedoresertib · A WEE1-path molecule on the floor
At #AACR26, Timothy Yap, MBBS, PhD (
@UTMDAnderson
) presents Phase I data of the combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations.
Key takeaways:
• First
Heat 11 · 7 likes · 0 replies · 4 reposts
Timothy A. Yap, Rahul Aggarwal, Elisa Fontana, Martin Hojgaard, Benedito A. Carneiro, Linda Duska, Patricia LoRusso, Siddhartha Yadav, Stephanie Lheureux, Cara Mathews, Ryan H. Moy, Nehal Lakhani, Mia Weiss, Joan Tymon-Rosario, Gerardo Colon-Otero, Ignacio Garrido-Laguna, Elisabeth K. Lee, Esteban Rodrigo Imedio, Jonathan Wessen, Luke Piggott, Vito Dozio, Noemie Luong, Christophe Mas, Alison M. Schram
Read the abstract →Source: Moffitt Cancer Center · x.com